ENGN vs. ARCT, EOLS, BCYC, KIDS, PAHC, PLRX, IRON, MNMD, LAB, and YMAB
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Arcturus Therapeutics (ARCT), Evolus (EOLS), Bicycle Therapeutics (BCYC), OrthoPediatrics (KIDS), Phibro Animal Health (PAHC), Pliant Therapeutics (PLRX), Disc Medicine (IRON), Mind Medicine (MindMed) (MNMD), Standard BioTools (LAB), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
Arcturus Therapeutics (NASDAQ:ARCT) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Arcturus Therapeutics received 420 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 65.39% of users gave Arcturus Therapeutics an outperform vote.
enGene has a net margin of 0.00% compared to enGene's net margin of -81.59%. Arcturus Therapeutics' return on equity of 0.00% beat enGene's return on equity.
Arcturus Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500.
enGene has lower revenue, but higher earnings than Arcturus Therapeutics.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 13.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 13.7% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Arcturus Therapeutics currently has a consensus price target of $64.86, suggesting a potential upside of 137.92%. enGene has a consensus price target of $34.40, suggesting a potential upside of 141.74%. Given Arcturus Therapeutics' higher possible upside, analysts plainly believe enGene is more favorable than Arcturus Therapeutics.
In the previous week, enGene had 25 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 41 mentions for enGene and 16 mentions for Arcturus Therapeutics. enGene's average media sentiment score of 0.73 beat Arcturus Therapeutics' score of 0.19 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Summary
Arcturus Therapeutics and enGene tied by winning 7 of the 14 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
